This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bergua JM, Cabrera C, Gomez Arteta E, Prieto J . Reply to Rituximab in CD20 positive multiple myeloma. Leukemia 2008; e-pub ahead of print 1 November 2007.
Gozzetti A, Fabbri A, Lazzi S, Bocchia M, Lauria F . Reply to ‘Rituximab in CD20 positive multiple myeloma’. Leukemia 2007; 21: 1842–1843.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gozzetti, A., Fabbri, A., Lazzi, S. et al. Reply to ‘Rituximab activity in CD20-positive multiple myeloma’. Leukemia 22, 1083 (2008). https://doi.org/10.1038/sj.leu.2405011
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2405011
This article is cited by
-
Reply to Gozzetti et al.
Leukemia (2008)